SAGE Therapeutics Inc. (SAGE)

161.44
3.90 2.40
NASDAQ : Health Technology
Prev Close 165.33
Open 165.71
Day Low/High 161.12 / 166.01
52 Wk Low/High 79.88 / 193.56
Volume 237.11K
Avg Volume 361.90K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 8.45B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Notable Monday Option Activity: SAGE, TSRO, BLCM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 2,373 contracts have traded so far, representing approximately 237,300 underlying shares. That amounts to about 73% of SAGE's average daily trading volume over the past month of 324,910 shares.

Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data In Severe Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that The Lancet has published (online)...

Sage Therapeutics To Present At Goldman Sachs Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on June 1, 2017, the Compensation...

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

Sage Therapeutics Receives Fast Track Designation For SAGE-217 For The Treatment Of Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Analysts' Actions -- AIG, Kroger, Sysco, Whole Foods, Valero and More

Analysts' Actions -- AIG, Kroger, Sysco, Whole Foods, Valero and More

Here are Tuesday's top research calls, including an upgrade of AIG, downgrade of Valero and new coverage for Kroger, Whole Foods Markets and Sysco.

Sage Therapeutics Announces First Quarter 2017 Financial Results And Provides Pipeline Update

Sage Therapeutics, Inc. (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on May 1, 2017, the Compensation...

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Sage Therapeutics Announces Initiation Of Phase 1 Development And First Dosing Of SAGE-718

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it has initiated a Phase 1 single...

ILG, Wyndham Worldwide, Marriott Vacations Worldwide: 'Mad Money' Lightning Round

ILG, Wyndham Worldwide, Marriott Vacations Worldwide: 'Mad Money' Lightning Round

Jim Cramer is bullish on ILG, Wyndham Worldwide, Marriott Vacations Worldwide, plus Bank of America.

It's the Earnings, Not the Politics: Cramer's 'Mad Money' Recap (Tuesday 4/25/17)

It's the Earnings, Not the Politics: Cramer's 'Mad Money' Recap (Tuesday 4/25/17)

Jim Cramer maintains this rally is fueled by the strong performance of U.S. companies, but says it's worth assessing stock market valuations.

Sage Therapeutics To Report First Quarter 2017 Financial Results On Tuesday, May 9, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Therapeutics Appoints Michael Cloonan As Chief Business Officer And Expands Executive Team

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the appointment of Michael Cloonan as...

Sage Therapeutics To Present At American Academy Of Neurology 2017 Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations for brexanolone...

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Some recent high-flying biotechs may be preparing for their next surge.

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.

Sage Defies Adversity on Its Way Up

Sage Defies Adversity on Its Way Up

The stock keeps moving upwards, despite worries over pricing in biotech.

Chart of the Day: Sage Therapeutics

The stock defies the rhetoric and keeps going up.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on April 3, 2017, the Compensation...

Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest

Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest

Sage Therapeutics, Depomed and NantKwest were among the biotech stock movers in premarket trading on Friday.

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on March 1, 2017, the Compensation...

Sage Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update

Sage Therapeutics, Inc. (NASDAQ: SAGE) today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2016.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.

Sage Therapeutics To Report Fourth Quarter And Full Year 2016 Financial Results On Thursday, February 23, 2017

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

TheStreet Quant Rating: D (Sell)